argenx (NASDAQ:ARGX - Get Free Report)'s stock had its "buy" rating reaffirmed by HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $720.00 price objective on the stock. HC Wainwright's price objective suggests a potential upside of 20.23% from the company's previous close.
Several other analysts also recently weighed in on the stock. JMP Securities lifted their target price on shares of argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a report on Tuesday, January 14th. Guggenheim increased their target price on argenx from $775.00 to $1,100.00 and gave the stock a "buy" rating in a research note on Monday, March 10th. Sanford C. Bernstein raised argenx from a "market perform" rating to an "outperform" rating in a report on Monday, March 17th. Citigroup reaffirmed an "outperform" rating on shares of argenx in a report on Friday, February 28th. Finally, Wells Fargo & Company increased their price target on shares of argenx from $723.00 to $741.00 and gave the company an "overweight" rating in a report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, argenx currently has a consensus rating of "Moderate Buy" and a consensus price target of $690.33.
View Our Latest Stock Analysis on argenx
argenx Stock Up 3.1 %
ARGX stock traded up $17.93 during trading on Tuesday, hitting $598.87. The company had a trading volume of 333,287 shares, compared to its average volume of 307,092. The firm has a 50-day moving average price of $607.87 and a 200-day moving average price of $604.46. The firm has a market cap of $36.39 billion, a PE ratio of -680.53 and a beta of 0.60. argenx has a 1-year low of $352.77 and a 1-year high of $678.21.
argenx (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. Sell-side analysts anticipate that argenx will post 3.13 earnings per share for the current year.
Institutional Investors Weigh In On argenx
Several hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC raised its stake in shares of argenx by 17.2% in the 4th quarter. FMR LLC now owns 5,618,222 shares of the company's stock valued at $3,455,207,000 after purchasing an additional 824,750 shares in the last quarter. Lord Abbett & CO. LLC bought a new stake in argenx in the third quarter valued at about $88,339,000. Point72 Asset Management L.P. acquired a new stake in argenx during the fourth quarter valued at approximately $91,013,000. Allspring Global Investments Holdings LLC lifted its holdings in argenx by 38,152.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company's stock worth $89,391,000 after buying an additional 143,834 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in shares of argenx by 53,684.9% in the 1st quarter. GAMMA Investing LLC now owns 135,538 shares of the company's stock worth $802,200,000 after acquiring an additional 135,286 shares in the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.
argenx Company Profile
(
Get Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Further Reading
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
